Courtesy of Benzinga.
HeartWare International, Inc. (NASDAQ: HTWR) today confirmed that it has received a notice from Engaged Capital, LLC (“Engaged Capital”) nominating three director candidates for election to HeartWare’s Board of Directors (the “Board”) at the company’s 2016 Annual Meeting of Stockholders. HeartWare’s annual meeting, which historically has been held in June, has not yet been scheduled for 2016. HeartWare stockholders are not required to take any action at this time.
In addition to the notice, Engaged Capital commented on HeartWare’s pending acquisition of Valtech Cardio, Ltd. (“Valtech”), a privately held company that specializes in the development of innovative surgical and transcatheter valve repair and replacement devices for mitral and tricuspid regurgitation. HeartWare issued the following statement in response to Engaged Capital’s comments:
We disagree with Engaged Capital, which has become a HeartWare stockholder only recently and does not see the benefits of the Valtech transaction. We remain fully committed to this transaction and are encouraged by discussions with other stockholders as they have become more knowledgeable about strategic
